BioSpace News Archive

Newtopia Inc. (“Newtopia” or the “Company”) (TSXV: NEWU) (OTCQB: NEWUF), a tech-enabled whole health platform creating sustainable habits that prevent, slow, and reverse chronic disease, today announced that on September 14, 2022, at the Company’s annual and special meeting of shareholders (the “Meeting”).

Geron Corporation reported that it has granted non-statutory stock options to purchase an aggregate of 901,950 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.

Spexis AG, a clinical-stage biopharmaceutical company focused on rare diseases and oncology, announced the results of a Phase 1 clinical trial with balixafortide, a potent, specific and highly selective macrocycle inhibitor of CXCR4.

RELIEF THERAPEUTICS Holding SA announced that an Investigator Initiated Trial with Nexodyn for Epidermolysis Bullosa has received IRB approval and will shortly enroll participants at Ann & Robert H. Lurie Children’s Hospital of Chicago with Professor Amy Paller, M.D., Chair, Department of Dermatology, Feinberg School of Medicine, Northwestern University, serving as Principal Investigator.

Vicore Pharma Holding AB, a clinical-stage pharmaceutical company developing medicines stimulating the angiotensin II type 2 receptor, announces that intra-arterial administration of C21 results in a significant dose-dependent increase in local blood flow.

Inventiva reported its interim financial results for the six months ended June 30, 2022, and provided a corporate update.

The 28th annual BIO-Europe is back in person and will take place October 24-26, 2022 in Leipzig, Germany. After being delivered digitally over the last two years, the event is expected to bring together over 4,000 executives from biotech, pharma and finance companies to engage in 27,000+ one-to-one meetings.

GenScript USA Inc. is collaborating with researchers at the Gladstone-UCSF Institute of Genomic Immunology to advance the development of new, non-viral cell therapies that modify genomic sequences in the pursuit of more effective cell therapy products while limiting the cellular toxicity that is typically associated with previously available methods.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. District Court for the Northern District of West Virginia ruled in favor of the company in a patent infringement suit against Viatris related to sitagliptin, an active ingredient in JANUVIA, JANUMET and JANUMET XR.

Zynerba Pharmaceuticals, Inc. today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, will present at the Ladenburg Thalmann 2022 Healthcare Conference on Thursday, September 29, 2022, at 3:00 p.m. ET, and host investor meetings.